In this latest rapid-reference memory aid from Diabetes & Primary Care, Pam Brown summarises the doses, indications and licences of the SGLT2 inhibitor class of diabetes drugs in adults.
Update history
19 October 2023: Updated to reflect changes in licensing for empagliflozin.
How to minimise loss of muscle mass when using GLP-1-based therapies for weight loss.
26 Mar 2025